Significantly increased levels of FGF19 are detected in PBC patients treated with OCA, even at the dose of 5 mg/die [97,99,100], and therefore FGF19 levels are used as biomarker of OCA activity in clinical trials. Here, FGF19 is linked to primary biliary cholangitis.